Refractory malignant neoplasm

This trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL…

This early-stage trial tests a new cancer treatment called OTS-412, a modified virus designed to attack tumor cells. It is given alone or with hydroxyurea and the immunotherapy atezolizumab. The study includes 24 adults with advanced solid tumors that no longer respond to standar…

This early-stage trial tests whether a personalized vaccine, made from each patient's unique tumor mutations, can safely boost the effects of the immunotherapy drug pembrolizumab in people with advanced kidney cancer. The vaccine is designed to train the immune system to recogniz…

This study tests a drug called tislelizumab in about 72 adults with advanced solid tumors that no longer respond to standard treatments. Only patients with a specific gene signature (T cell inflamed GEP score) are eligible. The drug is given every three weeks to see if it can shr…

This study tests a combination of three drugs—firsekibart, tislelizumab, and lenvatinib—in people with advanced liver cancer that has a specific genetic change called a TP53 mutation. Participants must have already tried immunotherapy without success. The goal is to see if this d…

This phase II trial tests whether a special radiotherapy regimen followed by targeted therapy and immunotherapy can shrink tumors in people with advanced colorectal cancer that has not responded to prior treatments. About 33 participants will receive the treatment and be monitore…

This study tests a combination of chemotherapy drugs (liposomal irinotecan, vincristine, and temozolomide) with or without an additional drug (anlotinib) in children aged 3-18 whose solid tumors have returned or not responded to treatment. The goal is to see if this combination c…

This early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…

This phase 2 trial will test a combination of four treatments—cetuximab β (a targeted antibody), radiation, an immunotherapy drug (envafolimab), and a growth factor (GM-CSF)—in 40 adults with advanced solid tumors that have EGFR protein and are no longer responding to standard ca…

This study tests a combination of four drugs (homoharringtonine, a BCL-2 inhibitor, rituximab, and prednisone) in 62 adults with relapsed or refractory diffuse large B-cell lymphoma. The goal is to find the safest dose and see if the combo can shrink tumors. It's an early-phase t…

This study tests whether a two-step tumor profiling approach can reliably measure antibody-drug conjugate (ADC) target proteins in children and young adults with relapsed or refractory solid or central nervous system tumors. The approach uses bulk RNA sequencing to screen for tar…